ValuEngine downgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a sell rating to a strong sell rating in a research note published on Wednesday morning.
A number of other equities research analysts have also recently commented on BCRX. HC Wainwright reaffirmed a buy rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, November 8th. Barclays initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, December 20th. They issued an equal weight rating and a $6.00 price target on the stock. Royal Bank of Canada raised shares of BioCryst Pharmaceuticals from a sector perform rating to an outperform rating and set a $6.00 price target on the stock in a research note on Tuesday, January 2nd. Finally, BidaskClub raised shares of BioCryst Pharmaceuticals from a strong sell rating to a sell rating in a research note on Thursday, February 8th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. BioCryst Pharmaceuticals presently has an average rating of Hold and an average price target of $8.29.
Shares of BioCryst Pharmaceuticals (NASDAQ BCRX) opened at $4.96 on Wednesday. BioCryst Pharmaceuticals has a one year low of $3.95 and a one year high of $9.25. The company has a current ratio of 2.53, a quick ratio of 2.53 and a debt-to-equity ratio of 0.21.
A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in BioCryst Pharmaceuticals by 15.0% in the 4th quarter. BlackRock Inc. now owns 7,614,280 shares of the biotechnology company’s stock valued at $37,386,000 after acquiring an additional 993,100 shares during the period. Vanguard Group Inc. grew its stake in BioCryst Pharmaceuticals by 19.9% in the 2nd quarter. Vanguard Group Inc. now owns 6,007,815 shares of the biotechnology company’s stock valued at $33,404,000 after acquiring an additional 996,052 shares during the period. Janus Henderson Group PLC acquired a new stake in BioCryst Pharmaceuticals in the 3rd quarter valued at $23,762,000. State Street Corp grew its stake in BioCryst Pharmaceuticals by 72.0% in the 2nd quarter. State Street Corp now owns 3,909,013 shares of the biotechnology company’s stock valued at $21,736,000 after acquiring an additional 1,636,909 shares during the period. Finally, RTW Investments LP grew its stake in BioCryst Pharmaceuticals by 1.4% in the 4th quarter. RTW Investments LP now owns 3,372,674 shares of the biotechnology company’s stock valued at $16,560,000 after acquiring an additional 47,969 shares during the period. 84.80% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://ledgergazette.com/2018/02/18/biocryst-pharmaceuticals-bcrx-downgraded-to-strong-sell-at-valuengine.html.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.